News
SNDX
8.81
-3.56%
-0.33
Syndax Pharmaceuticals Is Maintained at Buy by UBS
Dow Jones · 5h ago
Syndax Pharmaceuticals Price Target Cut to $31.00/Share From $33.00 by UBS
Dow Jones · 5h ago
UBS Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $31
Benzinga · 5h ago
Syndax price target lowered to $31 from $33 at UBS
TipRanks · 10h ago
UBS Sticks to Their Buy Rating for Syndax Pharmaceuticals (SNDX)
TipRanks · 10h ago
Weekly Report: what happened at SNDX last week (1109-1113)?
Weekly Report · 4d ago
Kura Oncology: Less Than Nothing By The First Readout
Seeking Alpha · 4d ago
Syndax Earnings Call Highlights Strong Growth and Pipeline Momentum
TipRanks · 5d ago
Syndax Pharmaceuticals (SNDX) Shareholder Investigation: MAXPIRe Trial Runs Out of Breath as Axatilimab Misses Its Mark
TipRanks · 11/09 19:45
Weekly Report: what happened at SNDX last week (1102-1106)?
Weekly Report · 11/09 09:49
Syndax Updates Revumenib Study for Patients With Organ Impairment
TipRanks · 11/06 16:31
Syndax selloff yesterday an overreaction, says H.C. Wainwright
TipRanks · 11/05 11:15
Syndax Pharmaceuticals Is Down 51% Even Though Sales Rose
Simply Wall St · 11/05 08:41
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 11/04 17:05
Syndax Pharmaceuticals: Revuforj Shows Strong Commercial Growth, But Frontline AML Is The Key
Seeking Alpha · 11/04 14:59
Syndax Pharmaceuticals (SNDX) Gets a Buy from B. Riley Securities
TipRanks · 11/04 14:15
Syndax Pharmaceuticals (SNDX) Stock Jumps After Q3 Results Expose Cash Strain
Simply Wall St · 11/04 00:37
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 11/03 17:30
Apple To $350? Here Are 10 Top Analyst Forecasts For Tuesday
Benzinga · 11/03 13:43
Syndax Posts Q3 Loss Narrows As Revenue Jumps 82% On Revuforj, Niktimvo Growth
NASDAQ · 11/03 13:26
More
Webull provides a variety of real-time SNDX stock news. You can receive the latest news about Syndax Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About SNDX
Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. It is focused on developing a pipeline of cancer therapies. Its product candidates include Revuforj and Niktimvo. It is developing Revuforj, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant AML. It is also exploring the use of Revuforj as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing Niktimvo, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.